Market
What will be the outcome of mRNA vaccine safety investigations in Australia by end of 2025?
2
Resolution / Starting Odds
No issues found • 25%
Minor issues found • 25%
Significant issues found • 25%
Undetermined • 25%
Official reports or findings from Australian health authorities or independent scientific bodies
Story
Australia Opens First mRNA Vaccine Facility, Government Maintains Vaccine Use Amid Safety Concerns
Dec 4, 2024, 07:43 AM
The Australian government has announced that it will not suspend the use of mRNA COVID-19 vaccines, despite concerns raised by some scientists regarding potential health risks, including an increased risk of cancer. This decision coincides with the opening of Australia's first mRNA vaccine manufacturing facility, which has the capacity to produce up to 100 million vaccine doses annually. The facility is intended to bolster the country's ability to protect its population from illnesses and diseases. Vaccine skepticism persists among segments of the population, as debates about the safety and efficacy of mRNA technology continue.
View original story
Similar markets
Comprehensive overhaul of vaccine policies • 25%
No changes recommended • 25%
Some vaccines recommended for elimination • 25%
Enhanced safety protocols recommended • 25%
No significant action • 25%
Further studies commissioned • 25%
Guideline updates • 25%
Vaccine suspension or recall • 25%
Revised guidelines • 25%
Other actions • 25%
No change • 25%
Increased studies • 25%
Suppression only in specific cases • 25%
No suppression found • 25%
Confirmed suppression • 25%
Inconclusive results • 25%
Other actions • 25%
No action taken • 25%
Conduct further studies • 25%
Issue new safety guidelines • 25%
Inconclusive results • 25%
Vaccines not linked to autism • 25%
Vaccines linked to autism • 25%
Investigation not completed • 25%
Link found • 25%
Inconclusive results • 25%
Investigation not completed • 25%
No link found • 25%
Contamination confirmed, no recall • 25%
Contamination confirmed, recall issued • 25%
Investigation inconclusive • 25%
No significant contamination found • 25%
Negative immunogenicity results • 25%
Negative safety results • 25%
Positive safety and immunogenicity results • 25%
Study inconclusive • 25%
Inconclusive • 25%
No report released • 25%
Inconclusive results • 25%
Link found • 25%
No link found • 25%
Investigation not completed • 25%
Vaccines not linked to autism • 25%
Vaccines linked to autism • 25%
Investigation incomplete • 25%
Confirms link • 25%
Minor negative impact • 25%
Positive impact • 25%
Significant negative impact • 25%
No impact • 25%
Unsuccessful • 25%
Successful with high efficacy • 25%
Successful with moderate efficacy • 25%
Trial inconclusive • 25%